麻醉概念

Search documents
恩华药业跌2.09%,成交额1.90亿元,主力资金净流出614.35万元
Xin Lang Cai Jing· 2025-10-10 06:31
恩华药业所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:价值成长、增持回购、 融资融券、中盘、麻醉概念等。 10月10日,恩华药业盘中下跌2.09%,截至14:13,报27.21元/股,成交1.90亿元,换手率0.78%,总市值 276.40亿元。 机构持仓方面,截止2025年6月30日,恩华药业十大流通股东中,南方中证500ETF(510500)位居第九 大流通股东,持股905.17万股,为新进股东。香港中央结算有限公司、中欧医疗健康混合A(003095) 退出十大流通股东之列。 资金流向方面,主力资金净流出614.35万元,特大单买入981.33万元,占比5.18%,卖出1872.27万元, 占比9.88%;大单买入4566.93万元,占比24.09%,卖出4290.34万元,占比22.63%。 恩华药业今年以来股价涨13.42%,近5个交易日跌5.19%,近20日涨11.79%,近60日涨28.59%。 截至6月30日,恩华药业股东户数4.36万,较上期增加30.17%;人均流通股20209股,较上期减少 23.19%。2025年1月-6月,恩华药业实现营业收入30.10亿元,同比增长8 ...
恒瑞医药涨2.11%,成交额18.46亿元,主力资金净流入1.69亿元
Xin Lang Cai Jing· 2025-09-30 03:23
Company Overview - Jiangsu Hengrui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various research areas including kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, hormone receptor regulation, DNA repair, and supportive therapies [2] - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, applicable in various fields such as autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology [2] - The main revenue composition is as follows: oncology 52.12%, neuroscience 15.33%, others (supplementary) 10.63%, contrast agents 9.82%, metabolic and cardiovascular 6.25%, others 3.07%, immunology and respiratory system 2.78% [2] Financial Performance - As of June 30, 2025, Hengrui Medicine achieved a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, with a year-on-year increase of 29.67% [3] - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the past three years [3] Stock Performance - On September 30, Hengrui Medicine's stock price increased by 2.11%, reaching 70.66 yuan per share, with a trading volume of 1.846 billion yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 468.985 billion yuan [1] - Year-to-date, the stock price has risen by 54.62%, with a 1.38% increase over the last five trading days, a 2.60% increase over the last twenty days, and a 32.32% increase over the last sixty days [1] - The net inflow of main funds was 169 million yuan, with significant buying and selling activities recorded [1]
复星医药跌2.01%,成交额1.82亿元,主力资金净流出1462.99万元
Xin Lang Zheng Quan· 2025-09-26 01:47
Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was established on May 31, 1995, and listed on August 7, 1998. The company is primarily engaged in drug manufacturing and research, covering medical devices, medical diagnostics, medical services, and pharmaceutical distribution and retail [1]. Financial Performance - For the first half of 2025, Fosun Pharma reported operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63%. However, the net profit attributable to shareholders increased by 38.96% to 1.702 billion yuan [2]. - The company has cumulatively distributed 12.593 billion yuan in dividends since its A-share listing, with 2.691 billion yuan distributed over the past three years [3]. Stock Performance - As of September 26, Fosun Pharma's stock price was 29.69 yuan per share, with a market capitalization of 79.285 billion yuan. The stock has increased by 21.02% year-to-date but has seen a decline of 4.01% over the past five trading days [1]. - The stock's trading volume on September 26 was 182 million yuan, with a turnover rate of 0.29% [1]. Shareholder Structure - As of June 30, 2025, Fosun Pharma had 230,000 shareholders, a decrease of 4.37% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - The top circulating shareholder is Hong Kong Central Clearing Limited, holding 75.881 million shares, an increase of 11.194 million shares from the previous period [3].
百利天恒涨2.06%,成交额2.00亿元,主力资金净流出1392.23万元
Xin Lang Zheng Quan· 2025-09-17 02:40
Core Viewpoint - The stock of Baile Tianheng has shown significant growth this year, with a 90.27% increase, despite a substantial decline in revenue and net profit reported for the first half of 2025 [1][2]. Group 1: Stock Performance - As of September 17, Baile Tianheng's stock price increased by 2.06%, reaching 364.80 CNY per share, with a trading volume of 200 million CNY and a turnover rate of 0.54% [1]. - The company has experienced a 90.27% increase in stock price year-to-date, with recent trading performance showing a 6.35% increase over the last five days, 16.99% over the last 20 days, and 22.05% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Baile Tianheng reported an operating revenue of 171 million CNY, a significant decrease of 96.92% year-on-year, and a net profit attributable to shareholders of -1.118 billion CNY, down 123.96% year-on-year [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 4.25% to 4,780, with an average of 21,525 circulating shares per shareholder, reflecting a 7.19% increase [2]. - The top ten circulating shareholders include notable funds such as Huaxia SSE Sci-Tech Innovation Board 50 ETF and others, with varying changes in their holdings [3].
百利天恒涨2.28%,成交额1.19亿元,主力资金净流出38.17万元
Xin Lang Cai Jing· 2025-08-29 03:08
Core Viewpoint - The stock price of Baili Tianheng has shown significant volatility, with a year-to-date increase of 72.89% but a recent slight decline in the last five trading days [2] Group 1: Stock Performance - As of August 29, Baili Tianheng's stock price rose by 2.28% to 331.48 CNY per share, with a trading volume of 1.19 billion CNY and a turnover rate of 0.36%, resulting in a total market capitalization of 132.92 billion CNY [1] - The stock has experienced a 0.07% decline over the last five trading days, an 8.62% increase over the last 20 days, and a 9.90% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Baili Tianheng reported a revenue of 171 million CNY, a significant year-on-year decrease of 96.92%, and a net profit attributable to shareholders of -1.118 billion CNY, reflecting a year-on-year decrease of 123.96% [2] Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders for Baili Tianheng increased by 4.25% to 4,780, with an average of 21,525 circulating shares per shareholder, up by 7.19% [2] - The top ten circulating shareholders include various funds, with notable changes such as a decrease in holdings by Huaxia Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF and an increase by China Europe Medical Health Mixed A [3]
恒瑞医药跌2.01%,成交额32.17亿元,主力资金净流出4.67亿元
Xin Lang Cai Jing· 2025-08-27 06:03
Core Viewpoint - Heng Rui Medicine's stock price has shown a significant increase of 40.02% year-to-date, indicating strong market performance despite recent fluctuations in trading volume and net capital outflow [2][3]. Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various medical conditions such as autoimmune diseases, cardiovascular diseases, and neurological disorders [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, up 29.67% from the previous year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the last three years [4]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% to 17,493 shares [3]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 535 million shares, and various ETFs that have increased their holdings [4].
恒瑞医药涨2.08%,成交额43.33亿元,主力资金净流入1.23亿元
Xin Lang Cai Jing· 2025-08-25 06:44
Core Viewpoint - Heng Rui Medicine's stock price has shown significant growth this year, with a 45.14% increase, indicating strong market performance and investor interest [2]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various therapeutic areas including pain management and cardiovascular diseases [2]. - The company's revenue composition includes oncology (52.12%), neuroscience (15.33%), imaging agents (9.82%), and other therapeutic areas [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% year-on-year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed in the last three years [4]. Stock Market Activity - As of August 25, Heng Rui Medicine's stock price was 66.33 yuan per share, with a market capitalization of 440.25 billion yuan [1]. - The stock has seen a net inflow of 123 million yuan from major funds, indicating strong buying interest [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% [3]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 14.3 million shares [4].
维力医疗跌2.01%,成交额4020.82万元,主力资金净流出596.71万元
Xin Lang Cai Jing· 2025-08-22 03:08
Core Viewpoint - The stock of Weili Medical has experienced fluctuations, with a recent decline of 2.01% on August 22, 2023, while the company has shown a year-to-date increase of 27.35% in stock price [1][2]. Group 1: Stock Performance - As of August 22, 2023, Weili Medical's stock price was 14.62 CNY per share, with a total market capitalization of 4.282 billion CNY [1]. - The stock has seen a decline of 1.35% over the last five trading days, an increase of 3.10% over the last 20 days, and a rise of 21.83% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Weili Medical reported a revenue of 745 million CNY, reflecting a year-on-year growth of 10.19% [2]. - The company has distributed a total of 634 million CNY in dividends since its A-share listing, with 393 million CNY distributed over the past three years [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Weili Medical was 17,300, a decrease of 1.81% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.85% to 16,885 shares [2]. - The ninth largest circulating shareholder, Huatai-PineBridge Medical Active Growth One-Year Mixed A, held 1.9757 million shares, a decrease of 414,600 shares from the previous period [2].